Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry

• Published in: Frontiers in immunology 2020-04, Vol.11, p.714-714
• Main Authors: Ranganath, Thanmayi, Simpson, Laura J, Ferreira, Anne-Maud, Seiler, Christof, Vendrame, Elena, Zhao, Nancy, Fontenot, Jason D, Holmes, Susan, Blish, Catherine A
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; CD4-Positive T-Lymphocytes - immunology; CD56 Antigen - metabolism; Cohort Studies; CyTOF/mass cytometry; Daclizumab - administration & dosage; daclizumab beta; Female; Humans; immune profiling; Immunology; Immunosuppressive Agents - administration & dosage; Killer Cells, Natural - drug effects; Killer Cells, Natural - immunology; Male; Mass Spectrometry - methods; Middle Aged; multiple sclerosis; Multiple Sclerosis - blood; Multiple Sclerosis - drug therapy; natural killer cell; Receptors, Natural Killer Cell - metabolism; uniform manifold approximation and projection; Young Adult
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2020.00714

Daclizumab beta is a humanized monoclonal antibody that binds to CD25 and selectively inhibits high-affinity IL-2 receptor signaling. As a former treatment for relapsing forms of multiple sclerosis (RMS), daclizumab beta induces robust expansion of the CD56 subpopulation of NK cells that is correlated with the drug's therapeutic effects. As NK cells represent a heterogeneous population of lymphocytes with a range of phenotypes and functions, the goal of this study was to better understand how daclizumab beta altered the NK cell repertoire to provide further insight into the possible mechanism(s) of action in RMS. We used mass cytometry to evaluate expression patterns of NK cell markers and provide a comprehensive assessment of the NK cell repertoire in individuals with RMS treated with daclizumab beta or placebo over the course of 1 year. Treatment with daclizumab beta significantly altered the NK cell repertoire compared to placebo treatment. As previously reported, daclizumab beta significantly increased expression of CD56 on total NK cells. Within the CD56 NK cells, treatment was associated with multiple phenotypic changes, including increased expression of NKG2A and NKp44, and diminished expression of CD244, CD57, and NKp46. These alterations occurred broadly across the CD56 population, and were not associated with a specific subset of CD56 NK cells. While the changes were less dramatic, CD56 NK cells responded distinctly to daclizumab beta treatment, with higher expression of CD2 and NKG2A, and lower expression of FAS-L, HLA-DR, NTB-A, NKp30, and Perforin. Together, these data indicate that the expanded CD56 NK cells share features of both immature and mature NK cells. These findings show that daclizumab beta treatment is associated with unique changes in NK cells that may enhance their ability to kill autoreactive T cells or to exert immunomodulatory functions.